PTN
Get informed when a big investor buys or sells
+ FollowOvervalued by 39.9% based on the discounted cash flow analysis.
| Market cap | $15.30 Million |
|---|---|
| Enterprise Value | $8.03 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.96 |
| Beta | -0.07 |
| Outstanding Shares | 3,921,182 |
| P/E Ratio | -1.64 |
|---|---|
| PEG | -1.72 |
| Price to Sales | 2.47 |
| Price to Book Ratio | 7.42 |
| Enterprise Value to Revenue | 0.61 |
| Enterprise Value to EBIT | -0.93 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.03 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 70.48%▼ 8.88% |
|---|---|
| Total Invested | $7.39M▼ 44.99% |
| Investors Holding | 250% |
No data
Palatin Technologies, Inc., established in Cranbury, New Jersey, in 1986, is a biopharmaceutical company focused on developing specialized, receptor-targeting therapeutics for various medical conditions within the United States. The firm...